Health care providers should not use non-invasive prenatal screening tests alone to diagnose genetic abnormalities due to the potential for false results, the Food and Drug Administration warned last week. Also known as cell-free DNA tests or non-invasive prenatal tests, these laboratory developed tests in most cases are not reviewed by the FDA.

“Patients and health care providers should be aware of the risks and limitations of using these genetic prenatal screening tests and that they should not be used alone to diagnose chromosomal (genetic) abnormalities,” FDA said, citing reports that some patients and providers have made critical health care decisions based on the results without additional confirmatory testing. 

Related News Articles

Headline
There have been 8,064 reported cases of whooping cough in the U.S. so far this year, according to the latest data from the Centers for Disease Control and…
Headline
A study published April 17 by BMC Infectious Diseases found increased incidents of Acinetobacter baumannii and carbapenem-resistant A. baumannii infections…
Headline
The incidence of invasive group A strep infections increased from 3.6 to 8.2 cases per 100,000 people from 2013 to 2022, according to a study authored by the…
Headline
The AHA Living Learning Network is launching the Quality Exchange, a virtual collaborative for health care quality and patient safety professionals at…
Headline
As part of the AHA's Patient Safety Initiative, a dedicated webpage features case studies showing how hospitals and health systems across the nation are…
Headline
The Kansas Department of Health and Environment this week reported an outbreak of 23 measles cases in southwest Kansas, nearly all of which occurred in…